<DOC>
	<DOCNO>NCT02441218</DOCNO>
	<brief_summary>The primary objective study demonstrate superiority ivabradine placebo reduction cardiovascular mortality hospitalisation worsen heart failure patient moderate severe symptom chronic heart failure , reduce leave ventricular ejection fraction currently receive recommend therapy disease .</brief_summary>
	<brief_title>Effects Ivabradine Cardiovascular Events Patients With Moderate Severe Chronic Heart Failure Left Ventricular Systolic Dysfunction . A Three-year International Multicentre Study</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Symptomatic Chronic heart failure ( NYHA II , III IV ) Left ventricular systolic dysfunction ( LVEF ≤ 35 % ) Sinus rhythm rest heart rate ≥ 70 bpm Optimal unchanged CHF medication dosages Unstable condition within previous 4 week Myocardial infarction coronary revascularisation within previous 2 month Stroke transient cerebral ischaemia within previous 4 week Congenital heart disease Severe valvular disease Active myocarditis Permanent atrial fibrillation flutter</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>